Kaplan-Meier estimates of overall survival and progression-free survival following nonmyeloablative allografts. Panel A shows the Kaplan-Meier estimate for myeloma for patients with responsive disease at study entry (CR + PR) and panel B shows the estimate for relapsed/refractory disease.